Dasatinib was also reported for its capacity to inhibit EphA2, Src family kinase particularly, FAK and Crk-associated substrate that consequently abolishes migration and invasion without any significant effect on melanoma cell viability or proliferation (Table 1) [58]. This evidence concerns the gene EPHA2 and melanoma.